Advertisement

International Journal of Hematology

, Volume 110, Issue 3, pp 381–384 | Cite as

Significance of biopsy with ERCP for diagnosis of bile duct invasion of DLBCL

  • Yusuke Ito
  • Masashi Miyauchi
  • Tomoka Nakamura
  • Naminatsu Takahara
  • Yousuke Nakai
  • Kazuki Taoka
  • Kazuhiro Toyama
  • Aya Shinozaki-Ushiku
  • Kazuhiko Koike
  • Mineo KurokawaEmail author
Case Report
  • 74 Downloads

Abstract

Obstructive jaundice is an initial symptom in 1–2% of diffuse large B cell lymphoma (DLBCL) cases. The major cause of bile duct obstruction in patients with DLBCL is extrinsic compression by enlarged lymph nodes. In such cases, the existence of bile duct invasion of lymphoma is rarely mentioned or observed pathologically, so the ratio of bile duct invasion to the total cases of obstructive jaundice, and its significance remains unknown. We report two cases of DLBCL presenting as an obstructive jaundice, in which we demonstrated bile duct invasion pathologically by biopsy from the wall of common bile duct with endoscopic retrograde cholangiopancreatography (ERCP). Endoscopic stent placement is a minimally invasive procedure to relieve cholestasis and is effective for diagnosing bile duct invasion. This procedure should thus be performed in all cases of obstructive jaundice caused by lymphoma to evaluate for bile duct invasion. Our cases suggest that ERCP may be useful as a diagnostic procedure for bile duct invasion.

Keywords

Diffuse large B cell lymphoma (DLBCL) Bile duct invasion Endoscopic retrograde cholangiopancreatography (ERCP) 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417–29.CrossRefGoogle Scholar
  2. 2.
    International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.CrossRefGoogle Scholar
  3. 3.
    Odemiş B, Parlak E, Başar O, Yüksel O, Sahin B. Biliary tract obstruction secondary to malignant lymphoma: experience at a referral center. Dig Dis Sci. 2007;52:2323–32.CrossRefGoogle Scholar
  4. 4.
    Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253–63.CrossRefGoogle Scholar
  5. 5.
    Fidias P, Carey RW, Grossbard ML. Non-Hodgkin's lymphoma presenting with biliary tract obstruction. A discussion of seven patients and a review of the literature. Cancer. 1995;75:1669–777.CrossRefGoogle Scholar
  6. 6.
    Chaudhari D, Khan S, Saleem A, Taylor T, Reddy C, Borthwick T, et al. Obstructive jaundice as an initial manifestation of non-Hodgkin lymphoma: treatment dilemma and high mortality. Case Rep Med. 2013;2013:259642.CrossRefGoogle Scholar
  7. 7.
    Bi XW, Zhang WW, Li ZM, Huang JJ, Xia Y, Sun P, et al. The extent of local tumor invasion predicts prognosis in stage IE nasal natural killer/T-cell lymphoma: a novel T staging system for risk stratification. Ann Hematol. 2015;94:1515–24.CrossRefGoogle Scholar
  8. 8.
    Harada S, Suzuki R, Uehira K, Yatabe Y, Kagami Y, Ogura M, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes. Leukemia. 1999;13:1441–7.CrossRefGoogle Scholar
  9. 9.
    Suguro M, Tagawa H, Kagami Y, Okamoto M, Ohshima K, Shiku H, et al. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci. 2006;97:868–74.CrossRefGoogle Scholar
  10. 10.
    Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010;21:2069–74.CrossRefGoogle Scholar
  11. 11.
    Tchambaz L, Schlatter C, Jakob M, Krähenbühl A, Wolf P, Krähenbühl S. Dose adaptation of antineoplastic drugs in patients with liver disease. Drug Saf. 2006;29:509–22.CrossRefGoogle Scholar
  12. 12.
    Riggs CE Jr, Benjamin RS, Serpick AA, Bachur NR. Bilary disposition of adriamycin. Clin Pharmacol Ther. 1977;22:234–41.CrossRefGoogle Scholar
  13. 13.
    Ross WA, Egwim CI, Wallace MJ, Wang M, Madoff DC, Lee JH. Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience. Dig Dis Sci. 2010;55:3271–7.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Yusuke Ito
    • 1
  • Masashi Miyauchi
    • 1
  • Tomoka Nakamura
    • 2
  • Naminatsu Takahara
    • 2
  • Yousuke Nakai
    • 2
  • Kazuki Taoka
    • 1
  • Kazuhiro Toyama
    • 1
  • Aya Shinozaki-Ushiku
    • 3
  • Kazuhiko Koike
    • 2
  • Mineo Kurokawa
    • 1
    • 4
    Email author
  1. 1.Department of Hematology and Oncology, Graduate School of MedicineThe University of TokyoTokyoJapan
  2. 2.Department of GastroenterologyThe University of TokyoTokyoJapan
  3. 3.Department of Pathology, Graduate School of MedicineThe University of TokyoTokyoJapan
  4. 4.Department of Cell Therapy and Transplantation MedicineThe University of Tokyo HospitalTokyoJapan

Personalised recommendations